MedTrace Logo

A Phase II Study of GC101 in NSCLC

NCT07560111 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-30

No results posted yet for this study

Summary

28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.

Conditions

  • Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes

A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.

Sponsors & Collaborators

  • Shanghai Juncell Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-06-01
Completion
2029-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07560111 on ClinicalTrials.gov